Adaptive Phage Therapeutics Raises $40.75M in Series B Financing
Adaptive Phage Therapeutics (APT), a Gaithersburg, Md.-based clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, closed a $40.75m Series B funding.
LEARN MORE